Antiviral drug remdesivir has "little or no effect" on a hospitalised Covid-19 patients' chances of survival, a World Health Organisation (WHO) clinical trial has suggested.
The potential coronavirus treatment option is one of four repurposed drugs being examined under the UN agency's large Solidarity trial that launched in March.
Randomised trials at hospitals around the world have involved remdesivir, lopinavir, hydroxychloroquine and interferon-beta 1a - looking to assess their impact on inpatient mortality.
The hydroxychloroquine and lopinavir arms of the trials were discontinued on June 20 and July 4 respectively. In a statement provided to the PA news agency on Thursday evening, the WHO press office said results from these first